CLM-SAP 16: Hypertriglyceridemia - Diagnosis, Pathophysiology, Clinical Significance and Treatment

3 ACPE 3 ANCC Contact Hours 3 CDR 3 AMA PRA Category 1 Credit(s)
Launch Date:
October 01, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Cardiologists, Cardiovascular Nurses, Endocrinologists, Family Practitioners, Internists, Lipidologists, Lipid Specialists, Nephrologists, Nurse Practitioners, Pharmacists and Dietitians, PhDs, physicians assistants, Primary Care Physicians

Relevant Terms:


1. Describe normal triglyceride physiology and pathophysiology 
2. Identify genetic and acquired disorders associated with hypertriglyceridemia 
3. Recognize the value of non-HDL-C in the diagnosis and treatment of triglyceride disorders 
4. Define treatment goals for patients with hypertriglyceridemia based on the most currently available guidelines, integrating results of clinical trials into comprehensive management strategies 
5. Describe pharmacologic and non-pharmacologic (diet and lifestyle modification) therapies used for the treatment of dyslipidemia and the management of hypertriglyceridemia 
6. Identify the relationship between serum triglyceride levels and risk for atherosclerotic cardiovascular disease 
7. Describe gender and ethnic differences in the clinical presentation of hypertriglyceridemia 
8. Define diagnostic criteria for type II diabetes and the association of insulin resistance to the development of dyslipidemia and cardiovascular disease 
9. Discuss the potential benefits of gastric bypass surgery in patients who are obese with other co-morbid conditions 
10. Discuss the management of hypertriglyceridemia in patients with HIV 

Hypertriglyceridemia is associated with an increased risk of cardiovascular events and acute pancreatitis. The reduction in elevated levels of non-HDL-C, a marker of increased concentrations of circulating triglyceride-rich lipoproteins, is associated with reduced atherosclerotic cardiovascular risk. Similarly, a reduction in markedly elevated serum triglyceride levels decreases the risk of pancreatitis. This program will provide strategies to integrate evidence-based medicine into daily practice in order to appropriately assess, manage, and treat patients with hypertriglyceridemia. 
RELEASE DATE: October 1, 2014
EXPIRATION DATE: September 30, 2017
ACTIVITY FORMAT: Internet activity enduring material
In order to receive credit for this enduring program, participants must answer each question, review the ensuing critiques and evaluate the activity. To receive credit you must obtain a 70% or greater total score on your Performance Score Report. A statement of credit will be available upon completion of an evaluation form. If you have questions about this CME/ CE activity, please contact the NLA at
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at within 4 weeks.
NLA and AKH have structured this exercise to actively engage the participant in discovery of their knowledge, and in their ability to apply into practice through clinical vignettes/case scenarios. Once the self-assessment questions are graded, the participant has the opportunity to review their answers and critiques for each question and seek out additional information through references provided.
Physicians who complete a program evaluation will receive a Statement of Continuing Education Credit from the NLA for up to 3 hours of AMA PRA Category 1 Credits™ toward the AMA Physician Recognition Award. 
CME credit provided by the National Lipid Association
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The National Lipid Association designates this enduring activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 3 Continuing Education Units (CPEUs) for completion of this activity. CDR Accredited Provider #NL0002.
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare
 AKH Inc., Advancing Knowledge in Healthcare is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. AKH Inc. approves this Application-based activity for 3 contact hour(s) (0.3CEUs). UAN 0077-9999-14-046-H04-P. Initial Release Date: October 1, 2014.
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 3 contact hours. 
Activity is jointly-provided by AKH Inc., Advancing Knowledge in Healthcare and the National Lipid Association.
This activity is supported by educational grants from Amarin and AstraZeneca.
Carl E. Orringer, MD, FACC, FNLA*
Associate Professor of Medicine
University of Miami Miller School of Medicine
Miami, FL
Karen E. Aspry, MD, MS, FACC*
Director, Lipid and Prevention Program
Lifespan Cardiovascular Institute
Assistant Professor of Medicine
Alpert Medical School of Brown University
East Greenwich, RI
Eliot A. Brinton, MD*
Director, Atherometabolic Research
Utah Foundation for Biomedical Research
Salt Lake City, UT
Kevin C. Maki, PhD, CLS, FNLAϯ
Chief Science Officer
Midwest Center for Metabolic and Cardiovascular Research
Glen Ellyn, IL
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA*
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director, Bellevue Hospital Lipid Clinic
New York, NY
*Denotes Diplomate, American Board of Clinical Lipidology.
†Denotes Diplomate, Accreditation Council for Clinical Lipidology.
Karen Aspry, MD
Merck & Co., Inc.
Contracted Research
Merck & Co., Inc.
Eliot Brinton, MD
Aegerion, Amarin, Amgen, Arisaph, AstraZeneca, Atherotech Inc., Eli Lilly & Co., Essentialis, Genzyme, Janssen Pharmaceuticals, Inc., Kowa Pharmaceuticals, Merck & Co., Inc., Novartis, Sanofi-aventis, Takeda Pharmaceuticals
Contracted Research
Amarin, Health Diagnostic Laboratory, Inc.,
Aegerion, Amarin, AstraZeneca, Daiichi Sankyo, Inc., Genzyme, Janssen Pharmaceuticals, Inc., Kowa Pharmaceuticals, Merck & Co., Inc., Takeda Pharmaceuticals
Kevin Maki, PhD
Advisory Board
Amarin, Omthera/ AstraZeneca, Pharmavite, LLC, Sancilio and Company, Inc., Trygg Pharmaceuticals
Abbott/ AbbVie Laboratories, Omthera/ AstraZeneca, Pharmavite, LLC, Trygg Pharmaceuticals
Contracted Research
Abbott/ AbbVie Laboratories,  DSM, Omthera/ AstraZeneca,  Pharmavite, LLC, Trygg Pharmaceuticals
Carl Orringer, MD
Merck & Co., Inc.
James Underberg, MD
Advisory Board
GlaxoSmithKline, Kowa Pharmaceuticals, Merck & Co., Inc.
Aegerion, Amarin, AstraZeneca, Eli Lilly & Co., Genzyme, LipoScience, Inc.,  Novartis
Contracted Research
Speakers Bureau
Daiichi Sankyo, Inc., GlaxoSmithKline, Kowa Pharmaceuticals, LipoScience, Inc., Merck & Co., Inc., Novartis
Robert Wild, MD, PhD, MPH
Disclosure Declaration
It is the policy of the NLA and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent  and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. NLA/AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. NLA, AKH Inc., the author(s) and the publisher specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of the content.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above